109 related articles for article (PubMed ID: 26439155)
1. Letter to the Editor: Comment on "FGF21 Response to Critical Illness: Effect of Blood Glucose Control and Relation With Cellular Stress and Survival" by Thiessen S.E., et al.
Plomgaard P; Weigert C
J Clin Endocrinol Metab; 2015 Oct; 100(10):L102-3. PubMed ID: 26439155
[No Abstract] [Full Text] [Related]
2. FGF21 Response to Critical Illness: Effect of Blood Glucose Control and Relation With Cellular Stress and Survival.
Thiessen SE; Vanhorebeek I; Derese I; Gunst J; Van den Berghe G
J Clin Endocrinol Metab; 2015 Oct; 100(10):E1319-27. PubMed ID: 26274346
[TBL] [Abstract][Full Text] [Related]
3. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.
Iglesias P; Selgas R; Romero S; Díez JJ
Eur J Endocrinol; 2012 Sep; 167(3):301-9. PubMed ID: 22740503
[TBL] [Abstract][Full Text] [Related]
4. Glucose control in the intensive care unit.
Fahy BG; Sheehy AM; Coursin DB
Crit Care Med; 2009 May; 37(5):1769-76. PubMed ID: 19325461
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and metabolic disturbances in critical illness: relation to mechanisms of organ dysfunction and adverse outcome.
Langouche L; Mesotten D; Vanhorebeek I
Verh K Acad Geneeskd Belg; 2010; 72(3-4):149-63. PubMed ID: 21067067
[TBL] [Abstract][Full Text] [Related]
6. Outside the limits of normal blood glucose during critical illness: failed homeostasis and quantifying allostatic load.
Branco RG; Tasker RC
Pediatr Crit Care Med; 2010 Nov; 11(6):755-7. PubMed ID: 21057268
[No Abstract] [Full Text] [Related]
7. Relationship of baseline glucose and mortality during medical critical illness?
Ligtenberg JJ; Meijering S; Vogelzang M; Nijsten MW; van der Horst IC; Tulleken JE; Zijlstra JG
Chest; 2005 Jun; 127(6):2283. PubMed ID: 15947353
[No Abstract] [Full Text] [Related]
8. Hyperglycaemia in critically ill patients: marker or mediator of mortality?
Corstjens AM; van der Horst IC; Zijlstra JG; Groeneveld AB; Zijlstra F; Tulleken JE; Ligtenberg JJ
Crit Care; 2006; 10(3):216. PubMed ID: 16834760
[TBL] [Abstract][Full Text] [Related]
9. Glycemic variability in critical illness and the end of Chapter 1.
Krinsley JS
Crit Care Med; 2010 Apr; 38(4):1206-8. PubMed ID: 20335697
[No Abstract] [Full Text] [Related]
10. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.
Cuevas-Ramos D; Almeda-Valdes P; Gómez-Pérez FJ; Meza-Arana CE; Cruz-Bautista I; Arellano-Campos O; Navarrete-López M; Aguilar-Salinas CA
Eur J Endocrinol; 2010 Sep; 163(3):469-77. PubMed ID: 20566587
[TBL] [Abstract][Full Text] [Related]
11. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation.
Strączkowski M; Karczewska-Kupczewska M; Adamska A; Otziomek E; Kowalska I; Nikołajuk A
Int J Obes (Lond); 2013 Oct; 37(10):1386-90. PubMed ID: 23419601
[TBL] [Abstract][Full Text] [Related]
12. Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes.
Murakami T; Ueba Y; Shinoto Y; Koga Y; Kaneda D; Hatoko T; Kato T; Yonemitsu S; Muro S; Oki S
Tohoku J Exp Med; 2016 Jun; 239(2):89-94. PubMed ID: 27212224
[TBL] [Abstract][Full Text] [Related]
13. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure.
Van der Zwan LP; Scheffer PG; Dekker JM; Stehouwer CD; Heine RJ; Teerlink T
Hypertension; 2010 Jun; 55(6):1366-72. PubMed ID: 20385972
[TBL] [Abstract][Full Text] [Related]
14. Tighten up glycemic control. Aggressive insulin therapy in critical care settings is the latest method of reducing mortality rates.
Spuhler VJ; Veale K
Nursing; 2007; 37 Suppl Critical():10-3. PubMed ID: 17440331
[No Abstract] [Full Text] [Related]
15. Dynamic change of serum FGF21 levels in response to glucose challenge in human.
Lin Z; Gong Q; Wu C; Yu J; Lu T; Pan X; Lin S; Li X
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1224-8. PubMed ID: 22539584
[TBL] [Abstract][Full Text] [Related]
16. Plasma FGF21 concentrations, adipose fibroblast growth factor receptor-1 and β-klotho expression decrease with fasting in northern elephant seals.
Suzuki M; Lee AY; Vázquez-Medina JP; Viscarra JA; Crocker DE; Ortiz RM
Gen Comp Endocrinol; 2015 May; 216():86-9. PubMed ID: 25857751
[TBL] [Abstract][Full Text] [Related]
17. Optimal control of glycemia among critically ill patients.
Van den Berghe G; Bouillon R
JAMA; 2004 Mar; 291(10):1198-9. PubMed ID: 15010439
[No Abstract] [Full Text] [Related]
18. Not too high, not too low.
Smith SD
Minn Med; 2005 Sep; 88(9):24-6. PubMed ID: 16475408
[No Abstract] [Full Text] [Related]
19. How to compare adequacy of algorithms to control blood glucose in the intensive care unit?
Van den Berghe G
Crit Care; 2004 Jun; 8(3):151-2. PubMed ID: 15153231
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.
Omar BA; Andersen B; Hald J; Raun K; Nishimura E; Ahrén B
Diabetes; 2014 Jan; 63(1):101-10. PubMed ID: 24062250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
